Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 12/20 | 0.67 |
| ▸ | IDO1 | P14902 | 12/20 | 0.67 |
| ▸ | IDO2 | Q6ZQW0 | 10/20 | 0.67 |
| ▸ | NPC1 | O15118 | 2/20 | 0.67 |
| ▸ | RAB9A | P51151 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | APAF1 | O14727 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | MITF | O75030 | 1/20 | 0.67 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.57 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.57 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4585623 | 0.86 | TDO2 (0.63) | TDO2IDO1IDO2NPC1RAB9A | |
| SCHEMBL31680506 | 0.80 | TDO2 (1.00) | TDO2IDO1IDO2NPC1RAB9A | |
| SCHEMBL9115231 | 0.80 | TDO2 (1.00) | TDO2IDO1IDO2NPC1RAB9A | |
| SCHEMBL9103165 | 0.78 | IDO1 (0.74) | TDO2IDO1IDO2NPC1RAB9A | |
| SCHEMBL9101821 | 0.77 | TDO2 (0.53) | TDO2IDO1IDO2NPC1RAB9A | |
| SCHEMBL4593015 | 0.75 | APAF1 (0.65) | TDO2IDO1IDO2NPC1RAB9A | |
| Tryptanthrin SCHEMBL29359262 | 0.73 | TDO2 (1.00) | TDO2IDO1IDO2NPC1RAB9A | |
| Tryptanthrin SCHEMBL2426211 | 0.73 | TDO2 (1.00) | TDO2IDO1IDO2NPC1RAB9A | |
| SCHEMBL9103006 | 0.70 | TDO2 (1.00) | TDO2IDO1IDO2NPC1RAB9A | |
| SCHEMBL9099548 | 0.69 | TDO2 (0.74) | TDO2IDO1IDO2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120244182-A1 | USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-09-27 | — | — | US | claimed |
| EP-1594524-B1 | USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2012-08-15 | — | — | EP | claimed |
| US-8193185-B2 | Administering a tryptanthrin compound, e.g., 8-nitroindolo[2,1-b]quinazoline-6,12-dione, to potentiate the immune response to an antigen; immunostimulants; small molecule immune potentiators; immunotherapy for infectious diseases; anticarcinogenic agents; vaccine adjuvant compositions and kits | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-06-05 | — | — | US | claimed |
| EP-1594524-A4 | USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-09-03 | — | — | EP | claimed |
| EP-1594524-A2 | USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION | CHIRON CORPORATION (US) | 2005-11-16 | — | — | EP | claimed |
| US-20040241192-A1 | Use of tryptanthrin compounds for immune potentiation | CHIRON CORPORATION (US) | 2004-12-02 | — | — | US | claimed |
| WO-2004064759-A2 | USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION | CHIRON CORPORATION (US) | 2004-08-05 | — | — | WO | claimed |
| US-20120244182-A1 | USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120244182-A1 | USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120244182-A1 | USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-09-27 | — | — | US | disclosed |
| EP-1594524-B1 | USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2012-08-15 | — | — | EP | disclosed |
| EP-1594524-B1 | USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2012-08-15 | — | — | EP | disclosed |
| US-8193185-B2 | Administering a tryptanthrin compound, e.g., 8-nitroindolo[2,1-b]quinazoline-6,12-dione, to potentiate the immune response to an antigen; immunostimulants; small molecule immune potentiators; immunotherapy for infectious diseases; anticarcinogenic agents; vaccine adjuvant compositions and kits | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| WO-2007098229-A2 | GELDANAMYCIN DERIVATIVES AND METHOD OF USE THEREOF | MICHIGAN STATE UNIVERSITY (US) | 2007-08-30 | — | — | WO | disclosed |
| EP-1682514-A1 | 11- O-METHYLGELDANAMYCIN COMPOUNDS | Kosan Biosciences, Inc. (US) | 2006-07-26 | — | — | EP | disclosed |
| EP-1594524-A2 | USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION | CHIRON CORPORATION (US) | 2005-11-16 | — | — | EP | disclosed |
| WO-2005056531-A1 | 11-O-METHYLGELDANAMYCIN COMPOUNDS | KOSAN BIOSCIENCES, INC. (US) | 2005-06-23 | — | — | WO | disclosed |
| US-20040241192-A1 | Use of tryptanthrin compounds for immune potentiation | CHIRON CORPORATION (US) | 2004-12-02 | — | — | US | disclosed |
| WO-2004064759-A2 | USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION | CHIRON CORPORATION (US) | 2004-08-05 | — | — | WO | disclosed |
| US-5441955-A | Tuberculosis | PATHOGENESIS CORPORATION (US) | 1995-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120244182-A1 | USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION | TPSG1, TPSB2, TPSAB1 | TDO2 66/4885IDO1 20/4885IDO2 19/4885 |
| US-20040241192-A1 | Use of tryptanthrin compounds for immune potentiation | TPSG1, TPSB2, TPSAB1 | TDO2 66/4885IDO1 20/4885IDO2 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.